Top Articles 2021

Top Articles on Atopic Dermatitis 2021: Chosen by the International Eczema Council.


  1. Nakatsuji, Teruaki et al. “Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial.” Nature medicine vol. 27,4 (2021): 700-709. doi:10.1038/s41591-021-01256-2
  2. Renert-Yuval, Yael et al. “The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults.” The Journal of allergy and clinical immunology vol. 148,1 (2021): 148-163. doi:10.1016/j.jaci.2021.01.001.
  3. Trier, Anna M et al. “IL-33 signaling in sensory neurons promotes dry skin itch.” The Journal of allergy and clinical immunology vol. 149,4 (2022): 1473-1480.e6. doi:10.1016/j.jaci.2021.09.014
  4. Bangert, Christine et al. “Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Rα blockade.” Science immunology vol. 6,55 (2021): eabe2749. doi:10.1126/sciimmunol.abe2749.
  5. Alkon, Natalia et al. “Single-cell analysis reveals innate lymphoid cell lineage infidelity in atopic dermatitis.” The Journal of allergy and clinical immunology vol. 149,2 (2022): 624-639. doi:10.1016/j.jaci.2021.07.025.


  1. Bieber, Thomas et al. “Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.” The New England journal of medicine vol. 384,12 (2021): 1101-1112. doi:10.1056/NEJMoa2019380
  2. Blauvelt, Andrew et al. “Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.” JAMA dermatology vol. 157,9 (2021): 1047-1055. doi:10.1001/jamadermatol.2021.30233.
  3. Guttman-Yassky, Emma et al. “Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.” Lancet (London, England) vol. 397,10290 (2021): 2151-2168. doi:10.1016/S0140-6736(21)00588-2.
  4. Papp, Kim et al. “Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.” Journal of the American Academy of Dermatology vol. 85,4 (2021): 863-872. doi:10.1016/j.jaad.2021.04.085.
  5. Silverberg, J I et al. “Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.” The British journal of dermatology vol. 184,3 (2021): 450-463. doi:10.1111/bjd.19573.


  1. Thomas, K S et al. “Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.” The British journal of dermatology vol. 185,1 (2021): 139-146. doi:10.1111/bjd.19751.
  2. Kelleher, Maeve M et al. “Skin care interventions in infants for preventing eczema and food allergy.” The Cochrane database of systematic reviews vol. 2,2 CD013534. 5 Feb. 2021, doi:10.1002/14651858.CD013534.pub2
  3. Maintz, Laura et al. “Machine Learning-Based Deep Phenotyping of Atopic Dermatitis: Severity-Associated Factors in Adolescent and Adult Patients.” JAMA dermatology vol. 157,12 (2021): 1414-1424. doi:10.1001/jamadermatol.2021.3668.
  4. Ungar, Benjamin et al. “COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab.” The journal of allergy and clinical immunology. In practice vol. 10,1 (2022): 134-142. doi:10.1016/j.jaip.2021.10.050.
  5. Thyssen, J P et al. “European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics.” Journal of the European Academy of Dermatology and Venereology : JEADV vol. 35,5 (2021): e308-e311. doi:10.1111/jdv.17167.

Click on the ‘Abstract’ link for above-referenced articles on PubMed, along with copyright information.